Clinical study of pravastatin in treatment of dyslipidemia after renal transplantation
- VernacularTitle:普伐他汀治疗肾移植术后血脂异常的临床研究
- Author:
Bo HAO
;
Changxi WANG
;
Keli ZHENG
;
Yuping DAI
;
Lizhong CHEN
;
Jiguang FEI
;
Suxiong DENG
;
Jiang QIU
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Pravastatin;
Dyslipidemia;
Endothelin;
Nitrous oxide;
Vasodilation
- From:
Chinese Journal of Postgraduates of Medicine
2006;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
6.2 mmol/L) who underwent renal transplantation accepted pravastatin therapy 10 mg once evening for 8 weeks. Total cholesterol(TC),low-density lipoprotein-cholesterol (LDL-C),high-density lipoprotein-cholesterol (HDL-C),triglyceride(TG),endothelin(ET) and nitrous oxide(NO) were measured before and after pravastatin therapy. The endothelium-dependent relaxing function was measured before and post pravastatin therapy by high-resolution ultrasound. Thirty people with normal blood cholesterol accepted same examination as control. Results The level of ET in renal transplantation group was significantly higher than that of control group,and the level of NO in renal transplantation group was significantly lower than that of control group. After 8 week′s therapy,the level of NO rose significantly,and the level of ET,TC,LDL-C,TG decreased significantly. The level of HDL-C increased but there was no significant difference between two groups. Flow-mediated vasodilations were improved after pravastatin therapy,while the level in transplantation group was lower than that of control group. Conclusion Pravastatin is effective in treatment of dyslipidemia after renal transplantation,which can improve the endothelium-dependent vasodilation.
